61 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification, Synthesis, and Biological Evaluation of the Major Human Metabolite of NLRP3 Inflammasome Inhibitor MCC950.
The University of Queensland
Discovery of NLRP3 inhibitors using machine learning: Identification of a hit compound to treat NLRP3 activation-driven diseases.
Peking University
Small molecule inhibitors of NLRP3 inflammasome and GSK-3β in the management of traumatic brain injury: A review.
National Institute of Pharmaceutical Education and Research (NIPER)
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.
Smith, Gambrell & Russell
Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis.
Sichuan University
Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen.
Fudan University
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
Smith, Gambrell & Russell
Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD Immunotherapy.
Fudan University
The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening.
BioAge Labs
Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer's disease.
Chonnam National University
Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
Sichuan University
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.
Novartis Biomedical Research
Design and Discovery of Novel NLRP3 Inhibitors and PET Imaging Radiotracers Based on a 1,2,3-Triazole-Bearing Scaffold.
Virginia Commonwealth University
Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023.
Shenyang Pharmaceutical University
Identification and Validation of PKR as a Direct Target for the Novel Sulfonamide-Substituted Tetrahydroquinoline Nonselective Inhibitor of the NLRP3 Inflammasome.
China Pharmaceutical University
Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity.
China Pharmaceutical University
Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis.
China Pharmaceutical University
Recent Progress and Prospects of Small Molecules for NLRP3 Inflammasome Inhibition.
Sichuan University
Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice.
Astrazeneca
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer.
University of Ferrara
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders.
Nodthera
Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis.
Sichuan University
Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease.
Smith, Gambrell & Russell
Fused Bicyclic Heteroaryl Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
Smith, Gambrell & Russell
Discovery of Novel NLRP3 Inflammasome Inhibitors Composed of an Oxazole Scaffold Bearing an Acylsulfamide.
Japan Tobacco
Advancements in Predictive Medicine: NLRP3 Inflammasome Inhibitors and AI-Driven Predictive Health Analytics.
Usona Institute
Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation.
University of Turin
1,2,4-Triazine Derivatives as NLRP3 Inhibitors for Treating Diseases.
Smith, Gambrell & Russell
Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis.
School of Pharmacy Anhui Medical University
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors.
Nodthera
Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies.
Virginia Commonwealth University
Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis.
Sichuan University
Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probes.
Shanghaitech University
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress.
Guizhou Medical University
Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis.
Anhui Medical University
MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice.
Zhejiang Chinese Medical University
Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis.
China Pharmaceutical University
Synthesis and biological evaluation of parthenolide derivatives with reduced toxicity as potential inhibitors of the NLRP3 inflammasome.
Guangzhou Medical University
Flavonoids with Inhibitory Effects on NLRP3 Inflammasome Activation from
Sichuan University
Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.
Cadila Healthcare
Discovery and optimization of 4-oxo-2-thioxo-thiazolidinones as NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inhibitors.
Xiamen University
Development of novel NLRP3-XOD dual inhibitors for the treatment of gout.
Soochow University
Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.
Shandong University
Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout.
Soochow University
Synthesis of deuterium-labelled analogues of NLRP3 inflammasome inhibitor MCC950.
The University of Queensland
Synthesis of 1,5-Anhydro-d-fructose derivatives and evaluation of their inflammasome inhibitors.
The Noguchi Institute
Compounds and compositions for treating conditions associated with NLRP activity
Novartis